Eli Lilly and Company
KRas G12C inhibitors
Last updated:
Abstract:
The present invention provides compounds of the Formula I below ##STR00001## where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
Status:
Grant
Type:
Utility
Filling date:
8 Oct 2019
Issue date:
6 Apr 2021